DCA Waiver DCA-20-14, Order Waiving Restrictions on Pharmacists Ordering and Collecting Specimens for COVID-19 Tests

The record

Jurisdiction

California Department of Consumer Affairs, Director (California State Board of Pharmacy); State level · California

Level

Sector regulator

Authority

Executive Order N-39-20; Cal. Gov't Code § 8571

Issued

2020-05-12 May 12, 2020

Effective

2020-05-12 (effective immediately) (read as 2020-05-12)

End

Terminates 60 days from the date of the order unless extended; extended by DCA-20-34 and superseded by DCA-20-45 (Ex. 031, Aug. 25, 2020) (read as 2020-08-25)

In force

May 12, 2020 to Aug. 25, 2020

Quarters

2020 Q22020 Q3

2020 Q22020 Q32020 Q42021 Q12021 Q22021 Q3

Limitation types

Health care ordersOther

Addressees

• California pharmacists
• pharmacies

Functions reached

• DX diagnostics (pharmacies as COVID-19 specimen-collection sites)
• SC pharmacy operations
• HR scope of practice
• CB patients

Collection

State health licensing boards AGY-ST-HEALTH-BOARDS

Operative words

Pursuant to Executive Order N-39-20, the Director waives Business and Professions Code section 4051, subdivision (b) and section 4052, subdivision (a)(12), to the extent those provisions would otherwise prohibit pharmacists from ordering or otherwise authorizing tests for the presence of the virus SARS-CoV-2 ('COVID 19 tests') in [patients, and from collecting specimens]. The waiver is subject to the following conditions: The test is authorized by the United States Food and Drug Administration (FDA) and is processed in a public health, commercial, or clinical laboratory pursuant to state and federal rules; and,... This order is effective immediately, and may be amended from time to time in the discretion of the Director. This order terminates 60 days from the date of the order, unless further extended.

Enforcement

Notes